Marksans Pharma Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Marksans Pharma kazanç ve gelirin sırasıyla yıllık 22.3% ve 16.2% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 22.4% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 18.7% olacağı tahmin edilmektedir.

Anahtar bilgiler

22.3%

Kazanç büyüme oranı

22.4%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	17.6%
Gelir büyüme oranı	16.2%
Gelecekteki özkaynak getirisi	18.7%
Analist kapsamı	Low
Son güncelleme	14 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected

Nov 27

Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

Oct 24

Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking

Sep 21

Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company

Jul 28

This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation

Sep 16

Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25

Sep 01

Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt

Jun 14

Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

May 27

Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?

Feb 19

Marksans Pharma Limited's (NSE:MARKSANS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Feb 04

Here's Why We Think Marksans Pharma (NSE:MARKSANS) Is Well Worth Watching

Jan 20

Do Institutions Own Marksans Pharma Limited (NSE:MARKSANS) Shares?

Jan 05

Kazanç ve Gelir Büyüme Tahminleri

NSEI:MARKSANS - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (INR Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
3/31/2027	35,839	6,047	4,354	4,360	3
3/31/2026	30,751	4,913	3,460	3,868	3
3/31/2025	26,607	3,970	1,963	2,945	2
9/30/2024	23,787	3,470	520	2,169	N/A
6/30/2024	22,680	3,338	N/A	N/A	N/A
3/31/2024	21,774	3,137	216	2,304	N/A
12/31/2023	21,034	3,164	N/A	N/A	N/A
9/30/2023	19,971	2,965	894	2,528	N/A
6/30/2023	19,184	2,743	N/A	N/A	N/A
3/31/2023	18,521	2,663	1,838	2,374	N/A
12/31/2022	17,842	2,123	N/A	N/A	N/A
9/30/2022	16,670	2,004	972	1,286	N/A
6/30/2022	15,756	1,847	N/A	N/A	N/A
3/31/2022	14,908	1,868	529	993	N/A
12/31/2021	14,069	2,367	N/A	N/A	N/A
9/30/2021	14,026	2,473	883	1,336	N/A
6/30/2021	14,064	2,518	N/A	N/A	N/A
3/31/2021	13,762	2,385	1,322	1,786	N/A
12/31/2020	13,817	2,018	N/A	N/A	N/A
9/30/2020	13,142	1,724	1,839	2,478	N/A
6/30/2020	12,203	1,476	N/A	N/A	N/A
3/31/2020	11,344	1,208	1,734	2,333	N/A
12/31/2019	10,463	879	N/A	N/A	N/A
9/30/2019	9,972	834	66	416	N/A
6/30/2019	10,099	780	N/A	N/A	N/A
3/31/2019	10,001	804	142	274	N/A
12/31/2018	9,523	666	N/A	N/A	N/A
9/30/2018	9,223	582	N/A	N/A	N/A
6/30/2018	9,272	463	N/A	N/A	N/A
3/31/2018	9,127	358	N/A	501	N/A
12/31/2017	8,918	343	N/A	N/A	N/A
9/30/2017	8,949	275	N/A	N/A	N/A
6/30/2017	8,015	187	N/A	N/A	N/A
3/31/2017	7,672	113	N/A	141	N/A
12/31/2016	7,926	70	N/A	N/A	N/A
9/30/2016	7,948	136	N/A	N/A	N/A
6/30/2016	8,699	481	N/A	N/A	N/A
3/31/2016	8,933	785	N/A	308	N/A
12/31/2015	8,536	1,093	N/A	N/A	N/A
9/30/2015	8,495	1,191	N/A	N/A	N/A
6/30/2015	8,045	1,154	N/A	N/A	N/A
3/31/2015	7,967	1,094	N/A	1,545	N/A
12/31/2014	7,850	950	N/A	N/A	N/A
9/30/2014	7,405	897	N/A	N/A	N/A
6/30/2014	6,914	786	N/A	N/A	N/A
3/31/2014	6,300	719	N/A	648	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: MARKSANS 'nin tahmini kazanç büyümesi (yıllık 22.3% ) tasarruf oranının ( 6.7% ) üzerindedir.

Kazançlar ve Piyasa: MARKSANS şirketinin kazançlarının (yıllık 22.3% ) Indian pazarından (yıllık 18.1% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: MARKSANS şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.

Gelir ve Pazar: MARKSANS şirketinin gelirinin (yıllık 16.2% ) Indian pazarından (yıllık 10.5% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: MARKSANS şirketinin gelirinin (yıllık 16.2% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: MARKSANS 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 18.7 %).

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/31 21:14
Gün Sonu Hisse Fiyatı	2024/12/31 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2024/03/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Marksans Pharma Limited 6 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Ranjit Kapadia	Centrum Broking Limited
Deepika Murarka	Choice Equity Broking Private Limited
Nitin Agarwal	DAM Capital Advisors

Marksans Pharma Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target increased by 26% to ₹330

Recent updates

Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected

Marksans Pharma Limited Receives USFDA Approval for Loratadine Tablets USP 10 mg

Price target increased by 26% to ₹330

Second quarter 2025 earnings released: EPS: ₹2.13 (vs ₹1.84 in 2Q 2024)

Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

Marksans Pharma Limited to Report Q2, 2025 Results on Nov 12, 2024

Marksans Pharma Limited Approves Dividend for the Year Ended March 31, 2024

Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking

Upcoming dividend of ₹0.60 per share

Insufficient new directors

Now 21% overvalued after recent price rise

Successful Closure of US FDA Inspection At Marksans Pharma's Manufacturing Facility Located At Verna, Goa

Investor sentiment improves as stock rises 17%

New minor risk - Share price stability

Marksans Pharma Limited, Annual General Meeting, Sep 24, 2024

First quarter 2025 earnings released: EPS: ₹1.96 (vs ₹1.52 in 1Q 2024)

Marksans Pharma Limited to Report Q1, 2025 Results on Aug 13, 2024

Now 20% overvalued after recent price rise

Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company

Investor sentiment improves as stock rises 18%

Whole-time Director recently bought ₹6.9m worth of stock

Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Full year 2024 earnings: EPS misses analyst expectations

Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?

Marksans Pharma Limited Recommends Final Dividend for the Financial Year 2023-24

Marksans Pharma Limited to Report Q4, 2024 Results on May 30, 2024

Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 23% overvalued after recent price rise

Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors

Marksans Pharma Limited to Report Q3, 2024 Results on Feb 13, 2024

We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease

Investor sentiment improves as stock rises 17%

Second quarter 2024 earnings released: EPS: ₹1.84 (vs ₹1.52 in 2Q 2023)

Marksans Pharma Limited to Report Q2, 2024 Results on Nov 09, 2023

Marksans Pharma Limited Appoints Shailaja Vardhan as an Independent Director

Marksans Pharma Ltd. Receives USFDA Approval for Guaifenesin Extended-Release Tablets

Marksans Pharma Limited Recommends Payment of Dividend for the Financial Year 2022-23

Full year 2023 earnings released: EPS: ₹6.39 (vs ₹4.56 in FY 2022)

Marksans Pharma Limited, Annual General Meeting, Aug 28, 2023

Insufficient new directors

Investor sentiment improves as stock rises 16%

Marksans Pharma Limited Announces That It Has Received Final Approval from the Us Food and Drug Administration for Its Abbreviated New Drug Application for Acetaminophen and Ibuprofen Tablets, 250 Mg/125 Mg

Marksans Pharma Limited Approves Declaration of Dividend for the Financial Year 2022-23, Payable on or After 12 June, 2023

Full year 2023 earnings released: EPS: ₹6.41 (vs ₹4.56 in FY 2022)

Marksans Pharma Limited to Report Q4, 2023 Results on May 30, 2023

Third quarter 2023 earnings released: EPS: ₹1.56 (vs ₹1.20 in 3Q 2022)

Marksans Pharma Limited to Report Q3, 2023 Results on Feb 13, 2023

Marksans Pharma Limited announced that it has received funding from OrbiMed Asia IV Mauritius FVCI Limited

Second quarter 2023 earnings released: EPS: ₹1.52 (vs ₹1.11 in 2Q 2022)

Marksans Pharma Limited to Report Q2, 2023 Results on Nov 14, 2022

Marksans Pharma Limited (BSE:524404) entered into a Business Transfer Agreement to acquire Bulk Pharmaceutical Business of Tevapharm India Private Limited.

Marksans Pharma Limited Declares Dividend, Payable on or After 20 September 2022

Upcoming dividend of ₹0.25 per share

Full year 2022 earnings released: EPS: ₹4.56 (vs ₹5.83 in FY 2021)

Marksans Pharma Limited to Report Q1, 2023 Results on Aug 13, 2022

Marksans Pharma Limited, Annual General Meeting, Aug 29, 2022

Marksans Pharma Limited Announces US FDA Approval for Pregabalin Capsules

Marksans Pharma Limited (BSE:524404) announces an Equity Buyback for INR 600 million worth of its shares.

Investor sentiment improved over the past week

Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly

Marksans Pharma Limited (BSE:524404) completed the acquisition of Access Healthcare for Medical Products LLC.

Marksans Pharma Recommends Final Dividend for the Financial Year Ended 31st March, 2022

Marksans Pharma Recommends Final Dividend for the Financial Year Ended 31st March, 2022

Full year 2022 earnings: EPS and revenues miss analyst expectations

Marksans Pharma Limited to Report Fiscal Year 2022 Results on May 30, 2022

Marksans Pharma Limited (BSE:524404) has signed agreement to acquire share capital of Access Healthcare for Medical Products LLC for AED 13 million.

Investor sentiment improved over the past week

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Marksans Pharma Limited to Report Q3, 2022 Results on Feb 11, 2022

Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Second quarter 2022 earnings released: EPS ₹1.11 (vs ₹1.21 in 2Q 2021)

This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation

Upcoming dividend of ₹0.25 per share